ACE and diabetes mellitus: Patients who died during follow-up had a lower prevalence of beta-blocker use and a higher prevalence of newly diagnosed diabetes, CAD history before admission, smoking history, and uses of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers (ARB), alpha blockers, and diuretics compared with patients who survived.